Sign in

    Charles River Laboratories International Inc (CRL)

    You might also like

    Charles River Laboratories International, Inc. (CRL) is a leading global partner in non-clinical drug development, offering a wide range of products and services to aid in the research, development, and manufacturing of new drugs, devices, and therapies . The company operates through three main segments, providing research models, discovery and safety assessment services, and manufacturing solutions . CRL's diverse portfolio helps clients streamline drug development processes, reduce costs, and accelerate time to market .

    1. Discovery and Safety Assessment (DSA) - Provides regulated and non-regulated services for drug discovery, non-clinical development, and safety testing, including therapeutic discovery, optimization, and safety assessment studies for various compounds.
    2. Research Models and Services (RMS) - Produces and sells small and large research models, offering related services such as Insourcing Solutions, Genetically Engineered Models and Services (GEMS), and Research Animal Diagnostic Services (RADS), along with vivarium space rental through the Charles River Accelerator and Development Lab (CRADL).
    3. Manufacturing Solutions - Includes Microbial Solutions, offering in vitro testing products, and Biologics Solutions, providing specialized testing and contract development and manufacturing services (CDMO) for biologics, including cell and gene therapies.
    NamePositionStart DateShort Bio
    James C. FosterChairman, President, Chief Executive Officer1976James C. Foster joined Charles River Laboratories in 1976 as General Counsel. He was named President in 1991, Chief Executive Officer in 1992, and Chair of the Board in 2000. Mr. Foster has been a director since 1989 .
    Flavia H. PeaseCorporate Executive Vice President, Chief Financial Officer2022Flavia H. Pease joined Charles River Laboratories in 2022. Before joining, she served as Vice President and Group Chief Financial Officer of Johnson & Johnson’s global Medical Devices businesses since 2019 .
    William D. BarboCorporate Executive Vice President1982William D. Barbo joined Charles River Laboratories in 1982 as a laboratory technician. He was named Corporate Vice President of Research Models and Services in 2005 and Corporate Executive Vice President and Chief Commercial Officer in October 2016 .
    Birgit GirshickCorporate Executive Vice President, Chief Operating Officer1989Birgit Girshick joined Charles River Laboratories in 1989. She was promoted to Chief Operating Officer in November 2021, adding the Research Models and Services and Microbial Solutions businesses to her responsibilities .
    Joseph W. LaPlumeCorporate Executive Vice President, Corporate Development and Strategy2005Joseph W. LaPlume joined Charles River Laboratories in 2005 as Senior Corporate Counsel. He became Corporate Executive Vice President, Corporate Development and Strategy in January 2019 .
    Victoria CreamerCorporate Executive Vice President, Chief People Officer2019Victoria Creamer joined Charles River Laboratories in January 2019 as Senior Vice President, Chief People Officer. She was promoted to Corporate Executive Vice President in October 2020 .
    Shannon ParisottoCorporate Executive Vice President2000Shannon Parisotto joined Charles River Laboratories in 2000. She was promoted to Corporate Executive Vice President in October 2022, assuming additional oversight of the Discovery Services business .
    1. With the planned closure or consolidation of approximately 15 smaller sites, how will you ensure that this reduction in global footprint won't limit your capacity to meet client demand when the market rebounds, and what measures are in place to prevent potential revenue loss due to these changes?

    2. Given that your restructuring initiatives are expected to generate approximately $200 million in cumulative annualized cost savings, eliminating more than 5% of your cost structure, is this sufficient to offset ongoing inflationary pressures and the restoration of incentive compensation, or do you anticipate additional cost-saving measures will be necessary to maintain margins in 2025?

    3. Can you provide more details on the implementation of the global business service model, specifically how it will streamline processes across functional areas, the expected timeline, and how it will impact your operational efficiency and margins?

    4. With large pharma clients continuing their cost-saving and reprioritization efforts, and demand from this segment softening in the back half of the year, what is your outlook for demand recovery in 2025, and how are you positioning the company to navigate this uncertain environment?

    5. In light of Vertex signing an agreement with Lonza for global manufacturing, does this pose a risk to your existing relationship with Vertex, and how do you plan to mitigate the impact of competitors entering agreements with key clients to ensure sustained demand for your services?

    Program DetailsProgram 1
    Approval DateAugust 2, 2024
    End Date/DurationNot specified
    Total additional amount$1 billion
    Remaining authorization$899.3 million
    DetailsReplaces prior authorization of $1.3 billion with $129.1 million remaining at termination

    Competitors mentioned in the company's latest 10K filing.

    • RMS Segment: Four main competitors, including one government-funded not-for-profit entity, one public company in the U.S., one privately held company in Europe, and one privately held company in the U.S.
    • DSA Segment (Discovery Services): Hundreds of competitors, with two main competitors being one public company in China and one public company in Europe.
    • DSA Segment (Safety Assessment): Dozens of competitors, with one main competitor being a division of a large public company in the U.S.
    • Manufacturing Segment (Microbial Solutions): Four main competitors, three of which are public companies in Europe and one is a private company in the U.S.
    • Manufacturing Segment (Biologics Solutions): Five main competitors, three of which are public companies in the U.S., one is a public company in Europe, and one is a public company in China.
    NameStart DateEnd DateReason for Change
    PricewaterhouseCoopers LLP1999 PresentCurrent auditor

    Recent developments and announcements about CRL.

    Financial Actions

      Debt Issuance

      ·
      Dec 14, 2024, 12:19 AM

      On December 13, 2024, Charles River Laboratories International, Inc. ("Charles River") amended and restated its existing credit agreement, known as the Tenth Amended and Restated Credit Agreement. This agreement involves several financial institutions and JPMorgan Chase Bank, N.A., as the administrative agent. Key changes include:

      • Extension of Maturity Date: The maturity date for the facilities has been extended.
      • Reduction in Revolving Commitments: The aggregate revolving commitments have been reduced from $3 billion to $2 billion.
      • Inclusion of Subsidiary as Borrower: Charles River Laboratories, Inc. ("CRL"), a direct subsidiary, is now a borrower under the credit agreement.
      • Security and Guarantees: The obligations under this agreement are guaranteed by CRL and secured by substantially all assets of Charles River, CRL, and any future material domestic subsidiaries. This includes a pledge of 100% of the capital stock of CRL and any future material domestic subsidiaries, and 65% of the capital stock of certain first-tier material foreign subsidiaries.

      The agreement provides for up to approximately $2 billion in financing through a revolving credit facility, available in multiple currencies including U.S. dollars, euros, and sterling. The facility matures on December 13, 2029, with no scheduled payments required before that date. Interest rates for loans under this agreement vary based on the currency and Charles River's leverage ratio.

      Potential Effects on Financial Health:

      • Liquidity: The reduction in revolving commitments from $3 billion to $2 billion may impact the company's liquidity, although the extended maturity date provides longer-term financial stability.
      • Leverage and Interest Coverage: The agreement includes tests for interest coverage and leverage ratios, which could affect the company's financial flexibility if not maintained.
      • Asset Security: The extensive asset security requirements could limit the company's ability to leverage these assets for other financial needs.

      Overall, while the agreement provides a substantial revolving credit facility, the reduced commitment and stringent covenants could have implications for Charles River's financial strategy and operational flexibility .